Stock ABCL ABCELLERA BIOLOGICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News AbCellera Biologics Inc.

Equities

ABCL

CA00288U1066

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-05-03 EDT 		5-day change 1st Jan Change
4.03 USD +4.68% Intraday chart for AbCellera Biologics Inc. +7.18% -29.42%
05-01 AbCellera Biologics Inc., Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies CI
03-11 AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
BU
AbCellera Biologics Inc., Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
CI
AbCellera Biologics : Corporate Overview
PU
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
BU
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
BU
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
BU
AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases
MT
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
BU
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
CI
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
BU
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
CI
AbCellera Announces Resignation of Board Member
AQ
AbCellera Announces Resignation of Board Member
BU
AbCellera Biologics Inc. Announces Board Changes
CI
AbCellera to Present at Upcoming Investor Conferences in March
BU
Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target is $9
MT
Stifel Lowers Price Target on AbCellera Biologics to $17 From $21, Maintains Buy Rating
MT
Transcript : AbCellera Biologics Inc., 2023 Earnings Call, Feb 20, 2024
AbCellera Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (ABCL) ABCELLERA BIOLOGICS Reports Fiscal 2023 Revenue $38M
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABCL Stock
  4. News AbCellera Biologics Inc.